SMO and familial pancreatic carcinoma: Preclinical trials explored SMO hedgehog inhibitors, such as cyclopamine, which were able to limit pancreatic cancer metastasis in a spontaneously metastasizing xenograft model and to influence chemoresistance to gemcitabine in pancreatic cancer cells [85].